2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 41% in 12 Months, According to Select Wall Street Analysts

Group 1 - Kenvue is the largest pure-play consumer health company globally, spun off from Johnson & Johnson in 2023, inheriting a strong product lineup [2] - Kenvue has a notable history as a Dividend King, with 63 consecutive annual dividend increases and a forward dividend yield exceeding 5.1% [3] - Despite its dividend strength, Kenvue's stock performance has been poor, with weak revenue growth and a significant decline in profits since becoming a standalone entity [3] Group 2 - Kenvue experienced a leadership change in July, appointing Kirk Perry as interim CEO following the departure of Thibaut Mongon [4] - The company faced a public relations crisis due to claims linking Tylenol use during pregnancy to autism, which Kenvue and several healthcare organizations quickly refuted [5] - Analysts from Bank of America and JPMorgan Chase suggest that Kenvue's stock may have upside potential of approximately 29%, with a total return exceeding 34% over the next 12 months if dividends are maintained [6]